AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] PTC Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cryoport (CYRX) Form 4 filing: On 07/24/2025 President & CEO Jerrell Shelton exercised 25,000 stock options at a $5 strike price (transaction code M) and retained every share. His direct common-stock holdings rose to 1,012,419 shares. The option grant, issued in 2015, vested monthly over four years; 50,000 options remain outstanding after the exercise. No shares were sold, representing an estimated $125,000 cash outlay and a modest increase in insider ownership. The move appears to be routine compensation-related activity rather than a strategic shift, yet the additional personal investment can be viewed as a sign of management confidence.

Deposito Form 4 di Cryoport (CYRX): Il 24/07/2025 il Presidente e CEO Jerrell Shelton ha esercitato 25.000 opzioni azionarie con un prezzo di esercizio di 5$ (codice transazione M) e ha mantenuto tutte le azioni. Le sue partecipazioni dirette in azioni ordinarie sono salite a 1.012.419 azioni. La concessione delle opzioni, emessa nel 2015, è stata maturata mensilmente in quattro anni; dopo l’esercizio restano 50.000 opzioni ancora in circolazione. Nessuna azione è stata venduta, comportando una spesa stimata di 125.000$ in contanti e un modesto aumento della proprietà interna. L’operazione sembra essere un’attività ordinaria legata alla compensazione piuttosto che un cambiamento strategico, ma l’investimento personale aggiuntivo può essere interpretato come un segnale di fiducia da parte della dirigenza.

Presentación del Formulario 4 de Cryoport (CYRX): El 24/07/2025, el Presidente y CEO Jerrell Shelton ejerció 25,000 opciones sobre acciones con un precio de ejercicio de 5$ (código de transacción M) y retuvo todas las acciones. Su participación directa en acciones comunes aumentó a 1,012,419 acciones. La concesión de opciones, emitida en 2015, se adquirió mensualmente durante cuatro años; tras el ejercicio quedan 50,000 opciones pendientes. No se vendió ninguna acción, lo que representa un desembolso estimado de 125,000$ en efectivo y un modesto aumento en la propiedad interna. La operación parece ser una actividad rutinaria relacionada con la compensación más que un cambio estratégico, aunque la inversión personal adicional puede verse como una señal de confianza de la gerencia.

Cryoport(CYRX) Form 4 제출: 2025ë…� 7ì›� 24ì�, 사장 ê²� CEOì� Jerrell Sheltonì� 행사가ê²� 5달러ë¡� 25,000ì£� ì£¼ì‹ ì˜µì…˜ì� 행사(거래 코드 M)하고 모든 주ì‹ì� 보유했습니다. ê·¸ì˜ ì§ì ‘ 보유 보통주는 1,012,419ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 2015ë…„ì— ë¶€ì—¬ëœ ì˜µì…˜ì€ 4ë…„ì— ê±¸ì³ ë§¤ì›” 권리가 ë°œìƒí–ˆìœ¼ë©�, 행사 í›� 50,000 옵션ì� 남아 있습니다. 주ì‹ì€ 매ë„하지 않아 ì•� 125,000달러 현금 ì§€ì¶�ê³� ê²½ì˜ì§� 보유 ì§€ë¶„ì˜ ì†Œí­ ì¦ê°€ë¥� 나타냅니ë‹�. ì´ë²ˆ 조치ëŠ� ì „ëžµì � 변화보다는 ë³´ìƒ ê´€ë � ì¼ìƒì ì¸ 활ë™ìœ¼ë¡œ ë³´ì´ë‚�, 추가 ê°œì¸ íˆ¬ìžëŠ� ê²½ì˜ì§� 신뢰ì� 표시ë¡� ë³� ìˆ� 있습니다.

Dépôt du Formulaire 4 de Cryoport (CYRX) : Le 24/07/2025, le président et PDG Jerrell Shelton a exercé 25 000 options d’achat d’actions à un prix d’exercice de 5$ (code de transaction M) et a conservé toutes les actions. Ses participations directes en actions ordinaires sont passées à 1 012 419 actions. L’attribution des options, accordée en 2015, a été acquise mensuellement sur quatre ans ; 50 000 options restent en circulation après l’exercice. Aucune action n’a été vendue, ce qui représente une dépense estimée à 125 000$ en liquidités et une légère augmentation de la participation des initiés. Ce mouvement semble être une activité de routine liée à la rémunération plutôt qu’un changement stratégique, mais cet investissement personnel supplémentaire peut être interprété comme un signe de confiance de la direction.

Cryoport (CYRX) Form 4 Einreichung: Am 24.07.2025 übte Präsident und CEO Jerrell Shelton 25.000 Aktienoptionen zum Ausübungspreis von 5$ aus (Transaktionscode M) und behielt alle Aktien. Sein direkter Bestand an Stammaktien stieg auf 1.012.419 Aktien. Der Optionszuteilung, die 2015 gewährt wurde, wurde monatlich über vier Jahre erworben; nach der Ausübung verbleiben 50.000 Optionen ausstehend. Es wurden keine Aktien verkauft, was einen geschätzten Bargeldaufwand von 125.000$ und eine moderate Steigerung des Insiderbesitzes darstellt. Der Schritt scheint eine routinemäßige, vergütungsbezogene Maßnahme zu sein und keine strategische Änderung, doch die zusätzliche persönliche Investition kann als Vertrauensbeweis des Managements gewertet werden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine option exercise; modest buy signals steady insider confidence, limited market impact.

The CEO converted 25 k in-the-money options at $5 and kept the resulting shares, lifting his direct stake to approximately one million. Because there was no simultaneous sale, the filing reflects a net purchase of roughly $125 k. The share count involved is small relative to Cryoport’s float and average volume, so price impact should be minimal. Investors may read the move as incremental alignment of management and shareholder interests, but it does not alter earnings outlook or capital structure.

Deposito Form 4 di Cryoport (CYRX): Il 24/07/2025 il Presidente e CEO Jerrell Shelton ha esercitato 25.000 opzioni azionarie con un prezzo di esercizio di 5$ (codice transazione M) e ha mantenuto tutte le azioni. Le sue partecipazioni dirette in azioni ordinarie sono salite a 1.012.419 azioni. La concessione delle opzioni, emessa nel 2015, è stata maturata mensilmente in quattro anni; dopo l’esercizio restano 50.000 opzioni ancora in circolazione. Nessuna azione è stata venduta, comportando una spesa stimata di 125.000$ in contanti e un modesto aumento della proprietà interna. L’operazione sembra essere un’attività ordinaria legata alla compensazione piuttosto che un cambiamento strategico, ma l’investimento personale aggiuntivo può essere interpretato come un segnale di fiducia da parte della dirigenza.

Presentación del Formulario 4 de Cryoport (CYRX): El 24/07/2025, el Presidente y CEO Jerrell Shelton ejerció 25,000 opciones sobre acciones con un precio de ejercicio de 5$ (código de transacción M) y retuvo todas las acciones. Su participación directa en acciones comunes aumentó a 1,012,419 acciones. La concesión de opciones, emitida en 2015, se adquirió mensualmente durante cuatro años; tras el ejercicio quedan 50,000 opciones pendientes. No se vendió ninguna acción, lo que representa un desembolso estimado de 125,000$ en efectivo y un modesto aumento en la propiedad interna. La operación parece ser una actividad rutinaria relacionada con la compensación más que un cambio estratégico, aunque la inversión personal adicional puede verse como una señal de confianza de la gerencia.

Cryoport(CYRX) Form 4 제출: 2025ë…� 7ì›� 24ì�, 사장 ê²� CEOì� Jerrell Sheltonì� 행사가ê²� 5달러ë¡� 25,000ì£� ì£¼ì‹ ì˜µì…˜ì� 행사(거래 코드 M)하고 모든 주ì‹ì� 보유했습니다. ê·¸ì˜ ì§ì ‘ 보유 보통주는 1,012,419ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 2015ë…„ì— ë¶€ì—¬ëœ ì˜µì…˜ì€ 4ë…„ì— ê±¸ì³ ë§¤ì›” 권리가 ë°œìƒí–ˆìœ¼ë©�, 행사 í›� 50,000 옵션ì� 남아 있습니다. 주ì‹ì€ 매ë„하지 않아 ì•� 125,000달러 현금 ì§€ì¶�ê³� ê²½ì˜ì§� 보유 ì§€ë¶„ì˜ ì†Œí­ ì¦ê°€ë¥� 나타냅니ë‹�. ì´ë²ˆ 조치ëŠ� ì „ëžµì � 변화보다는 ë³´ìƒ ê´€ë � ì¼ìƒì ì¸ 활ë™ìœ¼ë¡œ ë³´ì´ë‚�, 추가 ê°œì¸ íˆ¬ìžëŠ� ê²½ì˜ì§� 신뢰ì� 표시ë¡� ë³� ìˆ� 있습니다.

Dépôt du Formulaire 4 de Cryoport (CYRX) : Le 24/07/2025, le président et PDG Jerrell Shelton a exercé 25 000 options d’achat d’actions à un prix d’exercice de 5$ (code de transaction M) et a conservé toutes les actions. Ses participations directes en actions ordinaires sont passées à 1 012 419 actions. L’attribution des options, accordée en 2015, a été acquise mensuellement sur quatre ans ; 50 000 options restent en circulation après l’exercice. Aucune action n’a été vendue, ce qui représente une dépense estimée à 125 000$ en liquidités et une légère augmentation de la participation des initiés. Ce mouvement semble être une activité de routine liée à la rémunération plutôt qu’un changement stratégique, mais cet investissement personnel supplémentaire peut être interprété comme un signe de confiance de la direction.

Cryoport (CYRX) Form 4 Einreichung: Am 24.07.2025 übte Präsident und CEO Jerrell Shelton 25.000 Aktienoptionen zum Ausübungspreis von 5$ aus (Transaktionscode M) und behielt alle Aktien. Sein direkter Bestand an Stammaktien stieg auf 1.012.419 Aktien. Der Optionszuteilung, die 2015 gewährt wurde, wurde monatlich über vier Jahre erworben; nach der Ausübung verbleiben 50.000 Optionen ausstehend. Es wurden keine Aktien verkauft, was einen geschätzten Bargeldaufwand von 125.000$ und eine moderate Steigerung des Insiderbesitzes darstellt. Der Schritt scheint eine routinemäßige, vergütungsbezogene Maßnahme zu sein und keine strategische Änderung, doch die zusätzliche persönliche Investition kann als Vertrauensbeweis des Managements gewertet werden.

0001070081false00010700812025-07-282025-07-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2025

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

Delaware

    

001-35969

    

04-3416587

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

500 Warren Corporate Center Drive

    

Warren, NJ

07059

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 222-7000

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PTCT

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On July 28, 2025, PTC Therapeutics, Inc. (the “Company”), announced that the U.S. Food and Drug Administration (“FDA”) approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (“PKU”). Sephience is indicated for the treatment of hyperphenylalaninemia in adult and pediatric patients one month of age and older with sepiapterin-responsive PKU. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference into this Item 7.01. The Company will host a conference call on July 28, 2025 at 5:00 p.m. Eastern Time to discuss the approval. Instructions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.

The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

    

Description

99.1

Press Release, dated July 28, 2025 issued by PTC Therapeutics, Inc.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: July 28, 2025

By:

/s/ Pierre Gravier

Name:

Pierre Gravier

Title:

Chief Financial Officer

FAQ

What insider activity was reported for CYRX on 07/24/2025?

CEO Jerrell Shelton exercised 25,000 stock options at $5 and kept all resulting shares.

How many Cryoport shares does the CEO now own?

After the transaction, Shelton holds 1,012,419 shares directly.

What was the exercise price of the options?

The options were exercised at $5 per share.

Did the CEO sell any CYRX shares after exercising the options?

No. All 25,000 acquired shares were retained.

How many options remain outstanding for Jerrell Shelton?

He still holds 50,000 stock options after the reported exercise.
Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

3.55B
77.30M
2.46%
100%
4.8%
Biotechnology
Pharmaceutical Preparations
United States
WARREN